EVERSANA
Corporate brand
UnclaimedEVERSANA is an independent provider of global commercial services to the life sciences industry, with a Canadian presence in Burlington.
Last updated September 16, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
EVERSANA is a leading independent provider of global services to the life sciences industry, describing an integrated commercial services platform whose solutions span all stages of the product life cycle. The company serves more than 670 organizations, including innovative start-ups and established pharmaceutical companies. Its Canadian presence is associated with Burlington, Canada, and its news archive covers Canada-related topics such as reimbursement, pricing guidelines and partnerships.
History
EVERSANA describes itself as a leading independent provider of global services to the life sciences industry, built around an integrated commercial services platform. Its solutions are rooted in the patient experience and span all stages of the product life cycle, serving more than 670 organizations including innovative start-ups and established pharmaceutical companies. In July 2021, EVERSANA expanded its global commercialization solutions through the acquisition of Accelera Canada and its partner companies. In October 2021, EVERSANA was named a Great Place to Work for the third consecutive year in the U.S. and earned recognition in Canada, China and India. Its Canadian news archive also covers topics such as PMPRB budget impact analysis guidelines and CF drug reimbursement discussions.
Products and positioning
Leading independent provider of global services to the life sciences industry, with integrated solutions rooted in the patient experience.
Recent events
Reported
EVERSANA announces acquisition of Protean[6]
EVERSANA announced its acquisition of Protean, a market access consulting firm. Protean’s partners and team were to join EVERSANA effective immediately, and the Protean brand and proprietary tools were to be integrated in the coming months.
Reported
GENinCode and EVERSANA announce US commercialisation partnership[7]
GENinCode announced EVERSANA as its launch and commercialisation partner to access the United States market for GENinCode's portfolio of polygenic cardiovascular disease products.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/eversana-canada · Editorial policy · How profiles are compiled